No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AXSM240621P77500
- 2.20
- -0.25-10.20%
15min DelayClose Jun 20 15:59 ET
3.43High2.20Low
3.43Open2.45Pre Close50 Volume619 Open Interest77.50Strike Price12.23KTurnover111.87%IV-0.16%PremiumJun 21, 2024Expiry Date2.32Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6834Delta0.0794Gamma23.49Leverage Ratio-0.8792Theta-0.0015Rho-16.06Eff Leverage0.0143Vega
Intraday
- 5D
- Daily
News
Investors Ignore Increasing Losses at Axsome Therapeutics (NASDAQ:AXSM) as Stock Jumps 7.0% This Past Week
Citi's North America Focus List Updated, Adds: Coca-Cola, Evergy, Etc.
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $106 to $125
On Jun 12, major Wall Street analysts update their ratings for $Axsome Therapeutics(AXSM.US)$, with price targets ranging from $106 to $125.Morgan Stanley analyst Vikram Purohit maintains with a buy r
Investors Push Axsome Therapeutics (NASDAQ:AXSM) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well o
Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $106 Price Target
Mizuho analyst Graig Suvannavejh reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $106 price target.
Axsome Therapeutics Shares Continue To Fall
Comments
$Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $Axsome Therapeutics(AXSM.US$ $Macrogenics(MGNX.US$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
16
5
$Pfizer(PFE.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
8
1
1. $Annovis Bio(ANVS.US$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
7
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
Read more
Salmon Klein : are you in $Macrogenics (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
PaYtience Trader Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein PaYtience Trader: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
PaYtience Trader Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway